Status:
RECRUITING
A Study of V118E in Healthy Participants (V118E-003)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
18-49 years
Phase:
PHASE1
Brief Summary
Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called ...
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to the following:
- \- Is in good health before randomization
Exclusion
- The main exclusion criteria include but are not limited to the following:
- Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
- Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
Key Trial Info
Start Date :
October 8 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 8 2027
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT07168915
Start Date
October 8 2025
End Date
April 8 2027
Last Update
November 21 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Velocity Clinical Research, Hallandale Beach ( Site 0003)
Hallandale, Florida, United States, 33009
2
QPS-MRA, LLC-Early Phase ( Site 0002)
South Miami, Florida, United States, 33143
3
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0004)
Springfield, Missouri, United States, 65802
4
University of Texas Medical Branch ( Site 0001)
Galveston, Texas, United States, 77555-1115